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Conventional management of type 2 diabetes relies heavily 
on the principles of self-management. This is in essence 
a series of complex goal-directed behaviours required for 
lifestyle and behavioural changes as well as adherence to 
pharmacological interventions aimed at managing glycaemic 
control, hypertension, lipid profiles, weight and physical 
activity. Successful disease management is dependent on the 
patient’s ability to execute these interventions and maintain 
lifelong adherence.  Not only do people with type 2 diabetes 
have a greater rate of decline in cognitive functioning and 
risk of future dementia than people without diabetes,1,2 but 
the cognitive impairment is associated with poor diabetes 
control.3,4
The executive functioning domain of cognition is important 
in allowing the development of adaptive strategies and 
the ability of an individual to modify his/her behaviour 
in response to dynamic task requirements.5 Impairment of 
executive function has been clinically linked with functional 
impairment, poor medication adherence, increased level of 
care needed and even patient resistance to care.6-8 Executive 
impairment divorces ability from implementation.5 Type 2 
diabetes has been shown to be associated with impairment in 
executive cognitive functioning.6,9,10 This is attributed to frontal-
subcortical dysfunction due to microvascular disease.5,10
We sought to determine whether executive impairment as 
detected by a simple battery of beside executive function tests 
was associated with inadequate glycaemic control as defined 
by an HBA1c level ≥7%.
Patients and methods
People with type 2 diabetes attending the tertiary referral 
Diabetic Clinic at Groote Schuur Hospital, Cape Town, were 
invited to participate in the study during their usual clinic 
visits between 1 March 2006 and 31 June 2006. Groote Schuur 
Hospital is a university teaching hospital serving an open 
population of approximately 2.9 million persons. The clinic 
provides care for people with diabetes from lower socio-
economic income groups (more affluent patients with health 
insurance tend to seek medical care in the private sector), with 
poor disease control and/or established target organ damage. 
Study exclusion criteria included poor fluency in the English 
language, visual or hearing impairment, current management 
with an antidepressant, and/or precognitive evaluation blood 
glucose <4 mmol/l or >15 mmol/l on the day of assessment.
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Aims. Cognitive impairment in people with type 2 diabetes 
is a barrier to successful disease management. We sought to 
determine whether impaired executive function as detected by 
a battery of simple bedside cognitive tests of executive function 
was associated with inadequate glycaemic control.
Methods. People with type 2 diabetes attending a tertiary 
referral diabetic clinic who consented to participate in the 
study underwent a brief battery of cognitive testing (the 
Bedside Executive Screening Test) designed to detect executive 
function impairment.  Glycaemic control was determined 
using blood glycated haemoglobin levels (HBA1c). Inadequate 
glycaemic control was defined as HBA1c ≥7%.
Results. Executive function impairment was detected in 51 
(52%) of the 98 study participants. The presence of executive 
function impairment was significantly associated with poor 
glycaemic control (HBA1c ≥7%) (odds ratio 4.9, 95% confidence 
interval 1.3 - 18.8, p=0.019). There were no significant 
differences between patients with and without executive 
function impairment with regard to age, target organ damage, 
patient reported adherence, and hypoglycaemic therapy.  
Patients with a lower level of education were more likely to 
demonstrate executive impairment when glycaemic control 
was poor (p=0.013). 
Conclusions. Executive function impairment is common 
in a population of people with difficult-to-manage type 2 
diabetes. The presence of executive impairment is significantly 
associated with poor glycaemic control.
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Cognitive testing was performed using a battery we termed 
the Bedside Executive Screening Test (BEST). This comprised 
five parts:
• three item registration 
• three item delayed recall test 
•  executive clock drawing task part 1 (CLOX1): ‘draw me a clock 
that says 1:45. Put the numbers on the face so that a child could 
read them’11 
•  verbal fluency test: ‘name as many animals with 4 legs as you 
can think of in 1 minute’ 
•  problem solving task: ‘I have 18 books that I need to put on 2 
shelves. One of the shelves must have twice as many books on it as 
the other shelf. How many books must I put on each shelf?’
The latter three cognitive tests draw mainly on the cognitive 
domain of executive functioning.6,7 Abnormal tests were 
defined as: 
• CLOX1 score of <1011 
•  naming ≤12 animals (or ≤11 if patients had completed fewer 
than 9 years of education)12 
• inability to solve the problem correctly.
An assessment of executive impairment was made if patients 
had abnormal results for at least two of the three tests of 
executive functioning. The cognitive tests were administered 
according to a standardised proforma by either the attending 
clinician or a research nursing assistant. 
Clinical, demographic and laboratory characteristics were 
recorded at the time of assessment and included gender, 
age, level of education (in completed years), laboratory 
blood glucose and glycated haemoglobin level on the day 
of assessment, the presence or absence of microvascular 
(retinopathy, nephropathy, neuropathy) and macrovascular 
(ischaemic heart disease, peripheral vascular disease) 
complications, patient-reported dietary and medication 
adherence, and the various medications the patient reported 
using.
 All microvascular and macrovascular complications 
were defined according to our clinic protocol. A composite 
score of the three abovementioned microvascular and two 
abovementioned macrovascular complications was created.
Student’s t-test was used to determine the statistical 
difference between the means of age, years of education and 
total number of target organs damaged. The chi-square test 
was used to assess the statistical difference between dietary 
and medication adherence as well as the difference in drug 
use between patients with and without executive impairment. 
Fisher’s exact test was used to assess the statistical differences 
in diabetic control between those with and without executive 
impairment. The institutional Ethics Committee approved the 
study protocol and all study subjects gave written informed 
consent. 
Results
Of the one hundred and seven patients recruited, 98 consented 
to participation in the study. Women comprised 61 patients 
(62%). The mean age was 57.7 years (standard deviation (SD) 
10.4) (range 31 - 85 years), and the mean education level was 
8.2 years (SD 2.5) (range 3 - 16 years). Executive function 
impairment was present in 51 (52%) of the participants. For 
the clock drawing task (CLOX1) the mean score was 11.0 (SD 
3.2) (range 2 - 15), with 22 (22%) of patients scoring below 10 
(Fig. 1). The mean verbal fluency score was 10.3 (SD 3.2) (range 
4 - 27), with 70 patients (71%) naming fewer than 12 animals. 
Only 46 patients (47%) answered the book problem correctly, 
with 28 patients giving the answer as ‘9 and 9’.
Table I shows the demographic characteristics, diabetic 
control, reported adherence, target organ damage and drug 
usage differences between the study patients with and without 
executive impairment. 
Patients with executive impairment were more likely to have 
poor diabetic control (odds ratio 4.9, 95% confidence interval 
1.3 - 18.8).
Discussion
Our study population, in keeping with many other diabetes 
clinics throughout the world, comprised predominantly people 
with type 2 diabetes with inadequate glycaemic control and/or 
target organ damage. Education is shown to affect executive 
function.12 In our study patients with lower levels of education 
appeared more vulnerable to executive impairment when 
glycaemic control was inadequate.
The achievement of individualised glycaemic targets is 
challenging for people with diabetes.13 The observation that the 
Fig. 1. Examples of abnormal clocks drawn by study participants 
demonstrating executive cognitive impairment. CLOX score is 
indicated.
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presence of executive cognitive impairment was significantly 
associated with poor glycaemic control in this small study was 
therefore notable and potentially adds another dimension to 
the already complex interaction between health provider and 
patient.  Indeed, people with executive functioning deficits 
as detected by cognitive testing may require alternative 
management strategies to enhance disease control. 
Traditional bedside/clinic cognitive testing has used the 
Mini Mental State Examination, which does not adequately 
test for executive cognitive impairment, with poor 
sensitivity, especially in early disease.14 Formal batteries of 
neuropsychological tests are time consuming (taking up to 
3 hours to administer) and may not be available or practical 
in routine clinical practice. Even a validated test such as the 
Executive Interview takes 15 minutes to administer, too long 
for the busy diabetic clinic.15 Our bedside battery takes 5 
minutes or less to administer and requires minimal training 
beyond the scoring of the clock drawing task (CLOX1).11 
Clinicians are largely unaware that executive impairment 
may occur frequently in a variety of medical conditions, 
including diabetes.6 The findings of this study should be 
repeated in a larger study and may well provide impetus to 
perform a brief cognitive screening battery routinely – we 
propose the use of a battery such as ours. 
Specific strategies required to improve control in people 
with type 2 diabetes and executive impairment remain to 
be determined, but awareness and increased recognition 
of executive impairment is currently the greatest clinical 
challenge.
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Table I. Differences in demographic characteristics, diabetic control, reported adherence, target organ damage and drug usage 
between patients with and without executive impairment
                    Executive impairment 
                  Absent (N=47)            Present (N=51) 
Age (mean±SD)      56.2±10.0   59±10.7  NS
Years of education (mean±SD) 
HBA1c <7.0%      9.8±3.3   8.7±1.2  NS
HBA1c ≥7.0%       9.5±2.9   8.0±2.1  p=0.013
Diabetic control (N (%))   
HBA1c <7.0%      11 (23%)   3 (6%)  p=0.019
HBA1c ≥7.0%      36 (77%)   48 (94%) 
Patient reported adherence (N (%))   
Dietary       20 (43%)   27 (53%)*  NS
Medication      36 (77%)   36 (71%)  NS
Mean No. of target organs damaged (±SD)   1.4±1.3   1.7±1.2  NS
Drugs used (N (%))   
Metformin      32 (68%)   32 (63%)  NS
Sulphonylureas      18 (38%)   16 (31%)  NS
Insulin       37 (79%)   39 (76%)  NS
Aspirin      36 (77%)   32 (63%)  NS
Statin       18 (38%)   17 (33%)  NS
ACE inhibitors      36 (77%)   28 (71%)  p=0.041
*In 2 patients dietary adherence was unknown.
NS = not significant.
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